All Stories

  1. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis
  2. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?
  3. Metabolic disorders across hepatocellular carcinoma in Italy
  4. Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or fact?
  5. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study
  6. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
  7. Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2–5 February 2017
  8. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response
  9. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma
  10. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 2
  11. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1
  12. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma
  13. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma
  14. Curative therapies for hepatocellular carcinoma: an update and perspectives
  15. Recurrence of hepatocellular carcinoma after liver transplantation: an update
  16. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor
  17. Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice
  18. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
  19. Computed tomography of bowel obstruction: tricks of the trade
  20. Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis
  21. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
  22. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study
  23. Reply
  24. Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal?
  25. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
  26. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C
  27. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?
  28. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma
  29. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma
  30. Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma?
  31. EASL HCC summit: liver cancer management
  32. Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
  33. Determinants of alpha‐fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use
  34. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
  35. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results
  36. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
  37. Faculty of 1000 evaluation for Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
  38. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
  39. NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis
  40. Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response
  41. Rise and fall of HCV‐related hepatocellular carcinoma in Italy: a long‐term survey from the ITA.LI.CA centres
  42. Assessment of treatment response in hepatocellular carcinoma: a review of the literature
  43. Faculty Opinions recommendation of Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.
  44. Treatment of hepatocellular carcinoma: present and future
  45. Faculty Opinions recommendation of Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.
  46. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma
  47. Faculty Opinions recommendation of Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
  48. Causes of and Prevention Strategies for Hepatocellular Carcinoma
  49. Faculty Opinions recommendation of Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
  50. Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device—Initial observations
  51. Reply:
  52. Faculty Opinions recommendation of Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
  53. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study
  54. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
  55. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib
  56. Should cirrhosis change our attitude towards treating non‐hepatic cancer?
  57. Update on new approaches in the management of hepatocellular carcinoma
  58. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma
  59. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma
  60. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis
  61. Prognostic scores for hepatocellular carcinoma: none is the winner
  62. Multimodal approaches to the treatment of hepatocellular carcinoma
  63. Needle track seeding following percutaneous procedures for hepatocellular carcinoma
  64. Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance
  65. Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease
  66. Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease
  67. The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data
  68. Mortality in patients with hepatocellular carcinoma predicted by six scoring systems: None is the winner
  69. Treatment of hepatitis C: critical appraisal of the evidence
  70. Faculty of 1000 evaluation for Multidisciplinary management of hepatocellular carcinoma.